ERBB2 and cancer: The antimitotic activity was only detected in HER2-positive cancer cells, in contrast with the activity of its payload PM050489, which affected both HER2-positive and HER2-negative cancer cells, while MI130004 had suitable selectivity for cancer cells that overexpressed HER2.